AstraZeneca PLC (AZN)vsSanofi ADR (SNY)
AZN
AstraZeneca PLC
$160.17
+2.23%
HEALTHCARE · Cap: $252.33B
SNY
Sanofi ADR
$42.77
+0.12%
HEALTHCARE · Cap: $102.36B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 25% more annual revenue ($61.37B vs $48.92B). AZN leads profitability with a 17.0% profit margin vs 8.1%. AZN appears more attractively valued with a PEG of 1.28. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
SNY
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Margin of Safety
+7.8%
Fair Value
$51.00
Current Price
$42.77
$8.23 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Reasonable price relative to book value
Large-cap with strong market position
Strong operational efficiency at 21.0%
Generating 3.9B in free cash flow
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
ROE of 5.7% — below average capital efficiency
Expensive relative to growth rate
Earnings declined 91.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : SNY
The strongest argument for SNY centers on Price/Book, Market Cap, Operating Margin. Revenue growth of 14.6% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : SNY
The primary concerns for SNY are Return on Equity, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
AZN profiles as a mature stock while SNY is a value play — different risk/reward profiles.
SNY carries more volatility with a beta of 0.28 — expect wider price swings.
SNY is growing revenue faster at 14.6% — sustainability is the question.
SNY generates stronger free cash flow (3.9B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 49/100), backed by strong 17.0% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Sanofi ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?